The American Diabetes Association (ADA) is the organiser of the largest scientific meeting on diabetes in the world. This year, the 79th edition of the event took place at the Moscone Center in San Francisco, California, with 15,000 participants from 115 countries in attendance, including representatives of BIOTON S.A.
During the five-day event, the participants had the opportunity to take part in over 180 scientific sessions and learn from over 2,000 presentations of new research. For scientists and healthcare professionals, this was a unique opportunity to share their own ideas and discuss them with specialists from around the world, as well as to present the latest results of research on diabetes and its treatment.
At the conference, Dr. Monika Żurawska-Kliś from the Medical University of Łódź presented the work of the research programme GensuPen 2 entitled “Assessment of Effectiveness and Satisfaction of Use of the Automatic Injection System GensuPen 2”.
The aim of the study was to assess the effectiveness of the GensuPen 2 automatic injection system and the satisfaction level of patients who use it. It is a response to the needs of patients whose diabetic treatment depends largely on the convenience of use of therapeutic devices.
The results show that use of the GensuPen2 improves the metabolic control and quality of life of patients, increases their satisfaction with the treatment, and also reduces the pain of injection.
Participation in the conference was an excellent opportunity for the representatives of BIOTON S.A. to discuss the latest trends in the field of diabetes and to establish new relationships with specialists from around the world.